ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

benralizumab

Also written as “Benralizumab”, “Benralizumab 100 mg” and “KHK4563”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Churg-Strauss Syndrome · Nasal Polyps · Hypereosinophilic Syndrome, led by 2 companies.

Drug pageBenralizumab: every studyAll 67 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 10, 201948 company-led studies, 5 open or runningNext primary completion: Dec 23, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only465 open or runningphase 4since Apr 10, 2019Aug 6, 2007Dec 23, 2026phase 3 · NCT05692180
Kyowa Kirin20 open or runningphase 2since Aug 7, 2011Aug 7, 2011none ahead

Also a collaborator on its studies: Parexel, Iqvia Pty, Covance and PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Kyowa Kirin only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 7, 2011First study: phase 2 study in Uncontrolled and Suspected Eosinophilic AsthmaFirst studyNCT01412736 · 106 enrolled · Japan, Korea, Republic of
  2. Apr 25, 2016Phase 2 study in Eosinophilic Chronic RhinosinusitisNCT02772419 · 63 enrolled · Japan

TargetBeta

IL5RA →read by rule
“Interleukin-5 receptor subunit alpha inhibitor”ChEMBL 37, by rule

Studies

All 2 Kyowa Kirin leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02772419Eosinophilic Chronic Rhinosinusitis · Japan2CompletedMar 27, 201763
NCT01412736Uncontrolled and Suspected Eosinophilic Asthma · Japan, Korea, Republic of2CompletedJul 2013106

How it is read

Names in the registry

  • “Benralizumab”, 38 entries
  • “benralizumab”, 3 entries
  • “Benralizumab 100 mg”, 3 entries
  • “KHK4563”, 3 entries
  • “MEDI-563”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.